Centre de Référence des Pathologies Plaquettaires, Laboratoire d'hématologie, Pessac, France.
Platelets. 2010;21(2):94-100. doi: 10.3109/09537100903437206.
Point-of-care testing permits an evaluation of the efficacy of drugs used in the treatment of acute coronary syndromes (ACS). An increased risk of thrombosis after coronary stenting for ACS patients treated with aspirin and clopidogrel has been linked to high platelet reactivity and, for certain patients, poor drug response. The objective of our study was to compare the VerifyNow-P2Y12 device with the VASP (vasodilator-stimulated phosphoprotein) phosphorylation assay and ADP-induced platelet aggregation as assessed by light transmission aggregometry in a group of 81 ACS patients (100 tests) treated in our hospital. There was a good correlation between VerifyNow-P2Y12 and VASP especially during the chronic phase of one month or more after the ischemic event, whereas discordance was sometimes seen with platelet aggregometry. The rapidity and ease of use of the VerifyNow device suggests that it has a valuable place in point-of-care testing of ACS patients.
即时检测可用于评估急性冠状动脉综合征（ACS）治疗中使用的药物的疗效。接受阿司匹林和氯吡格雷治疗的 ACS 患者在冠状动脉支架置入术后血栓形成风险增加与血小板高反应性有关，对于某些患者而言，还与药物反应不良有关。我们的研究目的是比较 VerifyNow-P2Y12 设备与 VASP（血管扩张刺激磷蛋白）磷酸化测定以及在我院治疗的 81 例 ACS 患者（100 次检测）中通过光传输聚集法评估的 ADP 诱导的血小板聚集。VerifyNow-P2Y12 与 VASP 之间存在良好的相关性，特别是在缺血事件发生后一个月或更长时间的慢性期，而与血小板聚集法有时会出现不一致的情况。VerifyNow 设备的快速简便使用表明它在 ACS 患者即时检测中具有重要地位。
